Summarized by Masters of Longevity from Longevity Technology.
A biotech update on an AI-driven preclinical program that will rank mitochondria-targeting drug candidates to nominate a lead for preserving muscle.
Key Takeaways
- NorthStrive expanded its partnership with Yuva to advance four AI-identified mitochondrial drug candidates toward lead nomination.
- All four candidates previously increased ANT1 activity in human skeletal muscle cells in earlier preclinical testing.
- A six-month three-phase program will rank candidates, retest in mature muscle models, and profile mitochondrial biomarkers and energy output.
